Who are Abiraterone with Prednisone or Enzalutamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abiraterone-with-prednisone-or-enzalutamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Abiraterone with Prednisone or Enzalutamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abiraterone with Prednisone or Enzalutamide (Abiraterone with Prednisone or Enzalutamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone). Area: Oncology.

phase 3 CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Abiraterone with Prednisone or Enzalutamide (Abiraterone with Prednisone or Enzalutamide) — Curium US LLC. Abiraterone inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, together suppressing testosterone-driven prostate cancer growth; prednisone provides glucocorticoid support to mitigate mineralocorticoid excess from abiraterone.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abiraterone with Prednisone or Enzalutamide TARGET	Abiraterone with Prednisone or Enzalutamide	Curium US LLC	phase 3	CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone)	CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) class)

Curium US LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abiraterone with Prednisone or Enzalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone-with-prednisone-or-enzalutamide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab